United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 363.65 USD 1.13% Market Closed
Market Cap: 16.2B USD
Have any thoughts about
United Therapeutics Corp?
Write Note

United Therapeutics Corp
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Therapeutics Corp
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
United Therapeutics Corp
NASDAQ:UTHR
Net Income
$1.1B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

United Therapeutics Corp
Glance View

Market Cap
16.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the landscape of biotechnology, United Therapeutics Corp. has crafted a compelling narrative centered around innovation and transformation, principally targeting life-threatening conditions. Founded in 1996 by Martine Rothblatt, the company's inception was motivated by the urgent need to find solutions for her daughter's rare disease, pulmonary arterial hypertension (PAH). Over the years, United Therapeutics has stayed true to its pioneering ethos, focusing on creating and commercializing unique therapies that address the needs of patients with severe and often unmet health challenges. The core of its operations revolves around developing drugs that enhance survival and quality of life for individuals afflicted by PAH and other similar illnesses. Such dedication to research and pharmaceutical development has fostered a robust product pipeline, including therapeutics like Remodulin and Tyvaso, which play pivotal roles in the company's revenue generation. Financially, United Therapeutics sustains its momentum through a blend of strong patent portfolios and strategic market positioning, ensuring both competitive advantage and an ongoing revenue stream. By maintaining a keen focus on specific niches within the biotechnology sector, the company minimizes competition while maximizing the impact of its therapeutic solutions. Its business model thrives on the supply of specialized medications, which, given their critical nature, command premium pricing. Yet, United Therapeutics doesn’t solely pivot around drug sales; it is deeply invested in the future of medicine, notably venturing into areas like organ manufacturing and xenotransplantation, where it seeks to address broader and more complex health challenges. Through a blend of innovation, strategic partnerships, and diversification into emerging medical fields, United Therapeutics continues to cement its reputation as a leader in biotechnological advancement.

UTHR Intrinsic Value
375 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is United Therapeutics Corp's Net Income?
Net Income
1.1B USD

Based on the financial report for Sep 30, 2024, United Therapeutics Corp's Net Income amounts to 1.1B USD.

What is United Therapeutics Corp's Net Income growth rate?
Net Income CAGR 10Y
19%

Over the last year, the Net Income growth was 23%. The average annual Net Income growth rates for United Therapeutics Corp have been 34% over the past three years , and 19% over the past ten years .

Back to Top